# Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer

> **NCT04829890** · — · COMPLETED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 89 (actual)

## Conditions studied

- Breast Cancer
- Adenocarcinoma of Breast

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04829890
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-04
- **Final completion:** 2014-11
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829890, "Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04829890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*